Yasushi Hisamatsu1, Haruyasu Murakami2, Hiroaki Akamatsu2, Madoka Kimura2, Keita Mori3, Hisao Imai2, Akira Ono2, Takehito Shukuya4, Tetsuhiko Taira2, Hirotsugu Kenmotsu2, Tateaki Naito2, Masahiro Endo5, Takashi Nakajima6, Toshiaki Takahashi2, Nobuyuki Yamamoto7. 1. Division of Thoracic Oncology, Shizuoka Cancer Center Shizuoka, Japan; Department of Medical Oncology, Oita University Hospital Oita, Japan. 2. Division of Thoracic Oncology, Shizuoka Cancer Center Shizuoka, Japan. 3. Division of Clinical Trial Coordination office, Shizuoka Cancer Center Shizuoka, Japan. 4. Division of Thoracic Oncology, Shizuoka Cancer Center Shizuoka, Japan; Department of Respiratory Medicine, School of Medicine, Juntendo University Tokyo, Japan. 5. Division of Diagnostic Radiology, Shizuoka Cancer Center Shizuoka, Japan. 6. Division of Diagnostic Pathology, Shizuoka Cancer Center Shizuoka, Japan. 7. Division of Thoracic Oncology, Shizuoka Cancer Center Shizuoka, Japan; The Third Department of Internal Medicine, Wakayama Medical University Wakayama, Japan.
Abstract
BACKGROUND: S-1 is a novel antimetabolic agent that inhibits thymidylate synthase. The expression of thymidylate synthase is higher in squamous (Sq) non-small cell lung cancer (NSCLC) than in non-Sq NSCLC. The aim of this retrospective study was to assess the efficacy of S-1 monotherapy for advanced NSCLC according to the histological subtype. METHODS: We reviewed the clinical records of patients with advanced NSCLC treated with S-1 monotherapy as second- or third-line therapy between May 2005 and July 2012 at the Shizuoka Cancer Center. RESULTS: A total of 71 patients were included in this retrospective study. Patient characteristics were similar in the Sq NSCLC (n = 15) and non-Sq NSCLC (n = 56) groups, except with regard to gender and smoking status. The overall response rates were 0% (95% confidence interval [CI] 0-17%) for Sq NSCLC and 11% (95% CI 3-19%) for non-Sq NSCLC (P = 0.33). For Sq NSCLC and non-Sq NSCLC, the median progression-free survival times were 2.1 and 2.8 months (P = 0.02), respectively, and the median overall survival times were 6.1 and 10.1 months (P = 0.01), respectively. CONCLUSION: S-1 monotherapy may be more effective in patients with non-Sq NSCLC than in those with Sq NSCLC.
BACKGROUND: S-1 is a novel antimetabolic agent that inhibits thymidylate synthase. The expression of thymidylate synthase is higher in squamous (Sq) non-small cell lung cancer (NSCLC) than in non-Sq NSCLC. The aim of this retrospective study was to assess the efficacy of S-1 monotherapy for advanced NSCLC according to the histological subtype. METHODS: We reviewed the clinical records of patients with advanced NSCLC treated with S-1 monotherapy as second- or third-line therapy between May 2005 and July 2012 at the Shizuoka Cancer Center. RESULTS: A total of 71 patients were included in this retrospective study. Patient characteristics were similar in the Sq NSCLC (n = 15) and non-Sq NSCLC (n = 56) groups, except with regard to gender and smoking status. The overall response rates were 0% (95% confidence interval [CI] 0-17%) for Sq NSCLC and 11% (95% CI 3-19%) for non-Sq NSCLC (P = 0.33). For Sq NSCLC and non-Sq NSCLC, the median progression-free survival times were 2.1 and 2.8 months (P = 0.02), respectively, and the median overall survival times were 6.1 and 10.1 months (P = 0.01), respectively. CONCLUSION: S-1 monotherapy may be more effective in patients with non-Sq NSCLC than in those with Sq NSCLC.
Authors: Giorgio Scagliotti; Thomas Brodowicz; Frances A Shepherd; Christoph Zielinski; Johan Vansteenkiste; Christian Manegold; Lorinda Simms; Frank Fossella; Katherine Sugarman; Chandra P Belani Journal: J Thorac Oncol Date: 2011-01 Impact factor: 15.609
Authors: Paolo Ceppi; Marco Volante; Silvia Saviozzi; Ida Rapa; Silvia Novello; Alberto Cambieri; Marco Lo Iacono; Susanna Cappia; Mauro Papotti; Giorgio V Scagliotti Journal: Cancer Date: 2006-10-01 Impact factor: 6.860
Authors: K Takezawa; I Okamoto; W Okamoto; M Takeda; K Sakai; S Tsukioka; K Kuwata; H Yamaguchi; K Nishio; K Nakagawa Journal: Br J Cancer Date: 2011-04-12 Impact factor: 7.640